InMed’s CEO, Eric A. Adams, joins The Dales Report webcast to talk about the 2023 plans for the company’s rare cannabinoid programs in epidermolysis bullosa (EB), glaucoma and neurodegenerative disease.
Eric explains that InMed expects to complete enrollment of the Phase 2 clinical trial in EB in March, conduct GLP and other preclinical studies in glaucoma to prepare for its clinical trials in 2024 and advance its neurodegenerative disease program in preclinical studies following promising studies demonstrating neuroprotective effects and enhanced neuronal function, which may be relevant for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s.
Eric talks about InMed’s library of patentable cannabinoid analogs.
Read the full article and watch the video on The Dales Report website.
